Nektar Phase 1 Data for CAR-T Cell Combo Therapy in Acute Lymphoblastic Leukemia

 – Relapse-free/progression-free survival for NKTR-255 plus CD19-22 CAR-T cell therapy at 12 months was double that of historical controls (67% vs 38%) –

– Eight of nine patients achieved complete remission, all without detectable MRD –

https://www.prnewswire.com/news-releases/nektar-announces-publication-in-blood-of-phase-1-data-for-novel-il-15-agonist-nktr-255-in-combination-with-autologous-cd19-22-car-t-cell-therapy-in-patients-with-b-cell-acute-lymphoblastic-leukemia-302279546.html